Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Jun 21, 2014 10:28am

148 Views

Post# 22682525

DMC ruling is still hanging out their!

With all the commotion with AF and Direct everyone should not forget that the DMC ruling could come at any time. I find the fact that he has put it off for so long to be very unusual. Now it may only be continue until the next review which would not move the stock. A ruling of futility would crush the stock, The third option is stop for effectiveness and the stock would explode. I expect the first but you never know.

Bullboard Posts

Gold vs. bitcoin, where should you invest?